Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Company disclosed results via an 8-K filing.
Kodiak Sciences Inc. (Nasdaq: KOD) announced that its investigational treatments, Zenkuda and tabirafusp-ted, met the primary endpoints in the pivotal DAYBREAK trial for wet age-related macular degeneration (wAMD). The results were disclosed in an 8-K filing with the Securities and Exchange Commission.
The DAYBREAK trial evaluated the efficacy and safety of Zenkuda and tabirafusp-ted in patients with wAMD. Both treatments demonstrated positive outcomes, meeting the primary endpoints set for the study. Further details on the trial results and next steps for these treatments will be provided in the coming weeks.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.